Patrick Lamy Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the transaction, the vice president now directly owns 33,492 shares of the company’s stock, valued at $1,910,048.76. This represents a 12.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Trading Up 2.5 %

Shares of Akero Therapeutics stock opened at $55.36 on Friday. Akero Therapeutics, Inc. has a fifty-two week low of $15.32 and a fifty-two week high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of -14.76 and a beta of -0.19. The stock has a 50 day moving average of $29.78 and a 200 day moving average of $28.69.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Akero Therapeutics by 54.4% during the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter. Janus Henderson Group PLC increased its stake in Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after buying an additional 201,225 shares during the period. RTW Investments LP lifted its holdings in Akero Therapeutics by 9.0% during the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after buying an additional 487,450 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Akero Therapeutics in the 3rd quarter valued at approximately $37,392,000. Finally, SG Americas Securities LLC grew its stake in shares of Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after acquiring an additional 583,486 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. HC Wainwright upped their price objective on Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup increased their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday. Morgan Stanley lifted their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday. Canaccord Genuity Group increased their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $35.00 to $63.00 in a research note on Thursday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $66.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.